We’re developing promising, new therapies to inhibit aberrant Rho GTPase signaling that promotes progression of cancers and other diseases.
Revere’s innovative platform combines in silico modeling and proprietary assays with high-throughput screening capabilities to discover novel Rac1 and Cdc42 inhibitors. These enable delivery of novel targeted therapeutics.
We are at the leading edge of developing small molecules to inhibit Rho GTPase activation, creating medicines to address cancers and other diseases inadequately treated with standard of care therapies.
